Marex Group’s Immunovant IMVT Stock Holding History

Marex Group’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,000	Closed	-$397K	–	1238
2026 Q1	$397K	Buy	+16,000	New	+$414K	﹤0.01%	691

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marex Group's IMVT Position: Q2 2026 in Review

Marex Group sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 16,000 shares — an estimated $397K sold.

Marex Group first reported a position in IMVT in Q1 2026 and held it in 1 quarter. The position peaked at $397K in Q1 2026. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Marex Group reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
Marex Group sold 16,000 Immunovant shares in Q2 2026, an estimated $397K.
Marex Group first reported a position in Immunovant in Q1 2026 and held it in 1 quarter.
Marex Group's Immunovant position peaked at $397K in Q1 2026.
227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.